# US 2023/0266328 A1 · Multiomic analysis of nanoparticle-coronas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0266328 A1
- Document ID: US20230266328A1
- Status: Published application
- Kind: A1
- Application number: 18/041,131
- Filed: 2021-08-09
- Published: 2023-08-24
- Earliest claimed: 2020-08-10
- Assignees: The University of Manchester
- Applicants: The University of Manchester
- Inventors: Marilena HADJIDEMETRIOU; Kostas KOSTARELOS; Lois GARDNER; Lana PAPAFILIPPOU
- Web page: https://patentgrep.com/patent/US20230266328A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/57545: of the ovaries
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5432: {Liposomes or microcapsules}
- G01N 33/54346: {Nanoparticles}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6851: Quantitative amplification
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods for simultaneously identifying and/or detecting distinct classes of biomarker in biofluid samples, such as blood.

## Claims

### Claim 1

A method of identifying biomarkers from two or more distinct biomolecule classes in a biofluid, wherein the method comprises:
(a) contacting a plurality of nanoparticles with a biofluid to allow a biomolecule corona to form on the surface of said nanoparticles;
(b) isolating the nanoparticles and surface-bound biomolecule corona; and
(c) analyzing the biomolecule corona to identify biomarkers from two or more distinct biomarker classes.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step (a) is performed in vivo by administering a plurality of nanoparticles to a subject or in vitro using a biofluid

### Claim 3 (depends on 2)

The method according to claim 2, wherein the nanoparticles are administered to a subject by intravenous injection.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the plurality of nanoparticles are incubated in the test biofluid sample in vitro under conditions to allow a biomolecule corona to form on the surface of said nanoparticles.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the analysis is conducted on a single biofluid sample.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the biofluid is a blood or blood fraction sample, optionally selected from serum or plasma.

### Claim 7 (depends on 1)

The method according to claim 1, wherein at least one of the biomarker classes is selected from the group consisting of: protein, nucleic acid and lipid (or complexes of these).

### Claim 8 (depends on 1)

The method according to claim 1, wherein the biomolecule corona is analyzed by two or more of proteomic, genomic and lipidomic analysis.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the biomolecule corona is analyzed by genomic analysis and at least one other biomarker class of analysis.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the biomolecule corona is analyzed by genomic analysis and proteomic and/or lipidomic and/or metabolomic analysis.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the nanoparticles are selected from liposomes, metallic nanoparticles (such as gold or silver), polymeric nanoparticles, fibre-shaped nanoparticles (such as carbon nanotubes and two dimensional nanoparticles such as graphene oxide nanoparticles; optionally wherein the nanoparticles are liposomes.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method according to claim 11, wherein the nanoparticles are negatively charged.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the nanoparticles with surface-bound biomolecule corona are isolated from the biofluid and purified to remove unbound and highly abundant biomolecules to allow identification of low abundant biomarkers; optionally wherein the nanoparticles with surface-bound biomolecule corona are isolated from the biofluid and purified to remove unbound and highly abundant biomolecules by a method comprising size exclusion chromatography followed by ultrafiltration.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method according to claim 1, wherein the biofluid sample analyzed is from a subject in a diseased state, such as cancer, optionally wherein the cancer is selected from the group consisting of: lung, melanoma or ovarian cancer.

### Claim 17 (depends on 1)

The method according to claim 1, wherein one of the biomarker classes being analyzed is nucleic acid, such as DNA or RNA; optionally wherein the nucleic acid is cell-free DNA (cfDNA), optionally wherein the cfDNA is genomic DNA.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method according to claim 17, wherein the amount or relative amount of total cell-free DNA (cfDNA) is determined.

### Claim 20 (depends on 17)

The method according to claim 17, wherein a specific nucleic acid sequence within the cell-free nucleic acid is determined, optionally wherein the specific nucleic acid is indicative of a disease, such as being or comprising a disease-associated mutation.

### Claim 21 (depends on 1)

The method according to claim 1, wherein a change in a biomarker in a biofluid from a subject in response to therapy is monitored; optionally wherein the therapy comprises administration of a drug molecule to the subject, optionally wherein the drug molecule is an anti-cancer compound.

### Claim 22

(canceled)

### Claim 23

A method for detecting a disease state in a subject, comprising:
(a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles; and
(b) analyzing the biomolecule corona for one or more disease-specific biomarkers from two or more biomolecule classes, which is determinative of the presence of a disease in said subject.

### Claim 24

A method for monitoring cancer progression in a subject, comprising:
(a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles; and
(b) analyzing the biomolecule corona for one or more cancer-specific biomarkers from two or more biomolecule classes;
wherein the degree of cancer progression is determined based on the level of the cancer-specific biomarker(s) relative to a reference amount;
optionally wherein the cancer is selected from the group consisting of: ovarian, lung, prostate, melanoma and blood cancer, including leukemia, lymphoma and myeloma.

### Claim 25

(canceled)
